Identification and Treatment of the Liability to Develop Schizophrenia
Phase 4
- Conditions
- Schizophrenia
- Registration Number
- NCT00305474
- Lead Sponsor
- Central South University
- Brief Summary
This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Having at least one first-degree biological relative with schizophrenia and their age is between 19 and 59.
- Desire to participate in a medication trial.
- Is able to provide informed consent.
- Having moderate levels of negative symptoms, defined as 6 items rated 3 or higher on the Scale for the Assessment of Negative Symptoms (SANS).
- Scoring two or more standard deviations below normal in at least one of three cognitive domains: vigilance/working memory, long-term verbal memory, and executive functions.
- Scoring at least one standard deviation below normal in a second cognitive domain.
Exclusion Criteria
- IQ less than 80.
- Formal education less than 10 years.
- History of psychotic disorders.
- History of treatment with an antipsychotic medication.
- A substance abuse diagnosis within 6 months of diagnosis.
- A head injury with documented loss of consciousness exceeding 5 minutes (or subsequent cognitive deficits).
- A history of neurologic disease or damage.
- A medical condition with significant cognitive sequelae.
- A history of electroconvulsive treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Neuropsychological - cognitive measures 2003-2010
- Secondary Outcome Measures
Name Time Method Psychiatric Symptoms 2003-2010
Trial Locations
- Locations (1)
Mental Health Institute
🇨🇳Changsha, Hunan, China